CYP19A1 and breast carcinoma: These findings prompted the FDA to approve everolimus for the patients with ER+, HER2− advanced disease or its combination with exemestane for the treatment of relapse or progression after the use of nonsteroidal aromatase inhibitors in postmenopausal ER+/HER2− advanced breast cancer patients without visceral disease [25,105,106,108].